BergenBio Fundamentale Forhold (BGBIO)

[TekBot]

BERGENBIO RECEIVES FDA FAST TRACK DESIGNATION FOR BEMCENTINIB / ANTI-PD-(L)1 COMBINATION IN NSCLC

First recognition by a regulator of AXL-positive patients as a target population

Bergen, Norway, 08 June 2021?- BerGenBio ASA (OSE: BGBIO), a clinical-stage
…

Vis børsmeldingen

biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical need, today announces that the U.S. Food and Drug
Administration (FDA) has granted Fast Track designation for bemcentinib in
combination with an anti-PD-(L)1 agent for the treatment of patients with AXL
-positive advanced/metastatic non-small cell lung cancer (NSCLC).

The FDA’s decision represents the first recognition by a regulator of AXL
-positive patients as a molecular targetable patient population. This
designation has been granted for patients without actionable mutations, with
disease progression on or after treatment with an anti-PD-(L)-1 agent, with or
without chemotherapy as their first line of therapy.

Fast Track designation is intended to facilitate the development and review of
drugs used to treat serious conditions and to fill an unmet medical need. It
will enable BerGenBio to have more frequent interactions with the FDA throughout
the drug development process, so that an approved product can reach the market
faster.

The designation also provides Eligibility for Accelerated Approval, enabling
approval based on a surrogate clinical endpoint; Priority Review, which allows
New Drug Application (NDA) review in six months instead of 10, if relevant
criteria are met; and eligibility for Rolling Review, whereby the Company will
be able to submit completed sections of its NDA for review by the FDA before
complete application is submitted.

BerGenBio has developed proprietary biomarkers and companion diagnostic assays
for selection of AXL positive patients, the cAXL assay is validated for clinical
trial use. Retrospective analysis of patients in clinical trials suggest
approximately 50% of patients are cAXL positive, and it is these patients that
achieve the clinical responses and extended survival benefit previously
reported.

Richard Godfrey, Chief Executive Officer of BerGenBio, commented: “Building on
our encouraging clinical and translational data, we are excited to receive Fast
Track designation from the FDA for the promising combination of bemcentinib in
combination with a checkpoint inhibitor. This regulatory milestone is
particularly meaningful for BerGenBio, as it represents the first formal
recognition by a regulator of AXL-positive patients as a discernible patient
population and serves as further validation of our belief that AXL inhibition
has high potential as a cornerstone of cancer combination therapy. We look
forward to working closely with the FDA on the continued clinical development of
the combination.”

-Ends-

About AXL

AXL kinase is a cell membrane receptor and an essential mediator of the
biological mechanisms underlying life-threatening diseases.

In COVID-19, AXL has two synergistic mechanisms of action, it acts a co-receptor
to ACE2, to which the spike protein of the SARS-CoV-2 virus attaches and enters
the host cell, and AXL expression is upregulated that leads to suppression of
the Type 1 Interferon immune response by host cells and in their environment.
Research data confirms bemcentinib inhibits SARS-CoV-2 host cell entry and
promotes the anti-viral Type I interferon response. Data from a Phase II in
human clinical trial has shown that treatment with AXL inhibitor bemcentinib
increased the rate ventilator free survival in hospitalised COVID-19
patients.

In cancer, increase in AXL expression has been linked to key mechanisms of drug
resistance and immune escape by tumour cells, leading to aggressive metastatic
cancers. AXL suppresses the body’s immune response to tumours and drives
treatment failure across many cancers. High AXL expression defines a very poor
prognosis subgroup in most cancers. AXL inhibitors, such as bemcentinib,
therefore, have potential high value as monotherapy and as the cornerstone of
cancer combination therapy, addressing significant unmet medical needs and
multiple high-value market opportunities. Research has also shown that AXL
mediates other aggressive diseases including fibrosis

Composite AXL (cAXL) is a proprietary biomarker developed by BerGenBio that
simultaneously scores AXL expression on tumour cells and immune cells in the
tumour microenvironment, as determined by Immune Histo Chemistry (IHC) assay.
Data from on-going clinical trials suggest ca. 50% of patients are high cAXL and
this is predictive of improved clinical outcomes for patients receiving
bemcentinib.

About Bemcentinib

Bemcentinib (formerly known as BGB324), is a potential first-in-class, potent
and highly selective AXL inhibitor, currently in a broad phase II clinical
development programme. It is administered as an oral capsule and taken once per
day. Ongoing clinical trials are investigating bemcentinib in COVID-19, and
multiple solid and haematological tumours, in combination with current and
emerging therapies (including immunotherapies, targeted therapies and
chemotherapy), and as a single agent. Bemcentinib targets and binds to the
intracellular catalytic kinase domain of AXL receptor tyrosine kinase and
inhibits its activity.

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer, leukaemia
and COVID-19. A first-in-class functional blocking anti-AXL
antibody, tilvestamab, is undergoing phase I clinical testing. In
parallel, BerGenBio is developing a companion diagnostic test to identify
patient populations most likely to benefit from AXL inhibition: this is expected
to facilitate more efficient registration trials supporting a precision medicine
-based commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

Contacts

ir@bergenbio.com

Richard Godfrey CEO, BerGenBio ASA

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs

Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

Media Relations in Norway

Jan Petter Stiff, Crux Advisers

stiff@crux.no
+47 995 13 891

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to section 5-12 of the Norwegian Securities Trading Act.

Kilde

[vcp]

Super bull!
Så, snakker vi ned 8% i dag da

Får håpe short pakket må blø litt etterhvert!

[TekBot]

BERGENBIO ANNOUNCES LATE-BREAKING ABSTRACT PRESENTATION AT ECCMID 2021

Bergen, Norway, 10 June 2021?- BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical need, today announces that an analysis of its Phase II
…

Vis børsmeldingen

clinical trial of bemcentinib, a first-in-class selective oral AXL inhibitor, in
hospitalised COVID-19 patients has been selected as a late-breaking abstract at
the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID),
which will take place online from 9 - 12 July 2021.

Further details on the presentation will follow. To learn more, visit the ECCMID
website here: https://www.eccmid.org/

-Ends-

About AXL

AXL kinase is a cell membrane receptor and an essential mediator of the
biological mechanisms underlying life-threatening diseases.

In COVID-19, AXL has two synergistic mechanisms of action, it acts a co-receptor
to ACE2, to which the spike protein of the SARS-CoV-2 virus attaches and enters
the host cell, and AXL expression is upregulated that leads to suppression of
the Type 1 Interferon immune response by host cells and in their environment.
Research data confirms bemcentinib inhibits SARS-CoV-2 host cell entry and
promotes the anti-viral Type I interferon response. Data from a Phase II in
human clinical trial has shown that treatment with AXL inhibitor bemcentinib
increased the rate ventilator free survival in hospitalised COVID-19
patients.

In cancer, increase in AXL expression has been linked to key mechanisms of drug
resistance and immune escape by tumour cells, leading to aggressive metastatic
cancers. AXL suppresses the body’s immune response to tumours and drives
treatment failure across many cancers. High AXL expression defines a very poor
prognosis subgroup in most cancers. AXL inhibitors, such as bemcentinib,
therefore, have potential high value as monotherapy and as the cornerstone of
cancer combination therapy, addressing significant unmet medical needs and
multiple high-value market opportunities. Research has also shown that AXL
mediates other aggressive diseases including fibrosis

Composite AXL (cAXL) is a proprietary biomarker developed by BerGenBio that
simultaneously scores AXL expression on tumour cells and immune cells in the
tumour microenvironment, as determined by Immune Histo Chemistry (IHC) assay.
Data from on-going clinical trials suggest ca. 50% of patients are high cAXL and
this is predictive of improved clinical outcomes for patients receiving
bemcentinib.

About Bemcentinib

Bemcentinib (formerly known as BGB324), is a potential first-in-class, potent
and highly selective AXL inhibitor, currently in a broad phase II clinical
development programme. It is administered as an oral capsule and taken once per
day. Ongoing clinical trials are investigating bemcentinib in COVID-19, and
multiple solid and haematological tumours, in combination with current and
emerging therapies (including immunotherapies, targeted therapies and
chemotherapy), and as a single agent. Bemcentinib targets and binds to the
intracellular catalytic kinase domain of AXL receptor tyrosine kinase and
inhibits its activity.

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer, leukaemia
and COVID-19. A first-in-class functional blocking anti-AXL
antibody, tilvestamab, is undergoing phase I clinical testing. In
parallel, BerGenBio is developing a companion diagnostic test to identify
patient populations most likely to benefit from AXL inhibition: this is expected
to facilitate more efficient registration trials supporting a precision medicine
-based commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

Contacts

ir@bergenbio.com

Richard Godfrey CEO, BerGenBio ASA

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs

Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

Media Relations in Norway

Jan Petter Stiff, Crux Advisers

stiff@crux.no
+47 995 13 891

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[capitan01]

Kan noen forklare meg hvorfor Meteva plutselig oppføres med 2 kontoer på hhv 19 og 27 % av aksjene?

[vcp]

Rusk i maskineriet @PDX?

[TekBot]

BERGENBIO PRESENTS ENCOURAGING UPDATED PRELIMINARY DATA FROM PHASE II STUDY IN RELAPSED AML PATIENTS AT EHA VIRTUAL MEETING

Encouraging updated preliminary survival data more than double standard of care

reported in relapsed AML patients
…

Vis børsmeldingen

Bergen, Norway, 11 June 2021?- BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical need, will present updated preliminary survival data from
the ongoing Phase II study of bemcentinib (BGBC003) in combination with low dose
cytarabine (LDAC) in elderly relapsed Acute Myeloid Leukaemia (AML) patients at
the European Haematology Association (EHA) 2021 Virtual Meeting, taking place
from 9-17 June 2021.

An update will be provided from an expansion cohort of 27 relapsed/refractory
AML patients, who were assessed to explore safety and efficacy together with
translational analysis.

The data indicate that the combination of bemcentinib, a once-daily oral AXL
-inhibitor and LDAC is efficacious and well tolerated in the elderly and unfit
relapsed AML population. Durable responses were observed in the relapsed AML
setting, with an overall response rate of 31% (5/16) and median overall survival
of 13.3 months, currently still immature and potentially subject to change.

In a subset of eleven relapsed AML patients, who received two or more cycles of
the combination, an increased clinical benefit was demonstrated; a CR/CRi rate
of 36% (4/11) was observed, coupled with encouraging overall survival to date
(median OS not reached at >16 months) with several subjects continuing on the
study. In contrast, historic controls of LDAC monotherapy suggest CR/CRi rates
of 13-17% with median survival rates of 4.1-5.6 months, as reported by Sarkozy
et al. (2015) and Wei et al. (2020).

An in-depth translational research program to identify predictive molecular and
biological factors associated with response is ongoing.

Ongoing dialogue continues with the FDA and EMA regulatory agencies to align on
a pathway for a pivotal registration trial for the combination
of bemcentinib and LDAC in relapsed elderly AML patients unfit for intensive
chemotherapy.

Dr. Sonja Loges, Principal Investigator of the trial, commented: “We were
impressed to see these positive responses in relapsed AML patients, for whom
treatment options are very limited under the current standard of care.
Interestingly, the first complete responses were reported at a relatively late
stage in the trial, between week 13 and 15. These later onset responses could
reflect the importance of AXL mechanisms in disease development as well as the
potential immune promoting benefits of bemcentinib treatment. Further clinical
investigation of this promising combination is therefore warranted.”

Richard Godfrey, CEO of BerGenBio, commented: “We are very encouraged by this
promising preliminary response and survival data from the combination of
bemcentinib and LDAC in this patient population. Effective treatments with
meaningful survival benefit for relapsed AML patients is acknowledged as a
critical unmet medical need, this being a significant and rapidly growing
patient population as the first line treatment options improve. We continue to
work closely with the regulators in Europe and the US to align on the way
forward to embark on late-stage pivotal trial of bemcentinib in this combination
and patient population.”

The e-poster presentations are now available to watch online for registered
attendees here: https://ehaweb.org/congress/eha-congress-2021/program/featured
-sessions/.

Details of the e-poster presentation are below.

E-poster Title: THE COMBINATION OF AXL INHIBITOR BEMCENTINIB AND LOW-DOSE
CYTARABINE IS WELL TOLERATED AND EFFICACIOUS IN ELDERLY RELAPSED AML PATIENTS:
UPDATE FROM THE ONGOING BGBC003 PHASE II TRIAL (NCT02488408)

Abstract Number: EHA-2859

Session: 04. Acute Myeloid Leukaemia - Clinical

Date/Time: Available from 9am CEST on 11 June

-Ends-

About AXL

AXL kinase is a cell membrane receptor and an essential mediator of the
biological mechanisms underlying life-threatening diseases.

In COVID-19, AXL has two synergistic mechanisms of action, it acts a co-receptor
to ACE2, to which the spike protein of the SARS-CoV-2 virus attaches and enters
the host cell, and AXL expression is upregulated that leads to suppression of
the Type 1 Interferon immune response by host cells and in their environment.

Research data confirms bemcentinib inhibits SARS-CoV-2 host cell entry and
promotes the anti-viral Type I interferon response. Data from a Phase II in
human clinical trial has shown that treatment with AXL inhibitor bemcentinib
increased the rate ventilator free survival in hospitalised COVID-19 patients.

In cancer, increase in AXL expression has been linked to key mechanisms of drug
resistance and immune escape by tumour cells, leading to aggressive metastatic
cancers. AXL suppresses the body’s immune response to tumours and drives
treatment failure across many cancers. High AXL expression defines a very poor
prognosis subgroup in most cancers. AXL inhibitors, such as bemcentinib,
therefore, have potential high value as monotherapy and as the cornerstone of
cancer combination therapy, addressing significant unmet medical needs and
multiple high-value market opportunities. Research has also shown that AXL
mediates other aggressive diseases including fibrosis.

About Bemcentinib

Bemcentinib (formerly known as BGB324), is a potential first-in-class, potent
and highly selective AXL inhibitor, currently in a broad phase II clinical
development programme. It is administered as an oral capsule and taken once per
day. Ongoing clinical trials are investigating bemcentinib in COVID-19, and
multiple solid and haematological tumours, in combination with current and
emerging therapies (including immunotherapies, targeted therapies and
chemotherapy), and as a single agent. Bemcentinib targets and binds to the
intracellular catalytic kinase domain of AXL receptor tyrosine kinase and
inhibits its activity.

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer, leukaemia
and COVID-19. A first-in-class functional blocking anti-AXL
antibody, tilvestamab, is undergoing phase I clinical testing. In
parallel, BerGenBio is developing a companion diagnostic test to identify
patient populations most likely to benefit from AXL inhibition: this is expected
to facilitate more efficient registration trials supporting a precision medicine
-based commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com

Contacts

ir@bergenbio.com

Richard Godfrey CEO, BerGenBio ASA

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs

Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

Media Relations in Norway

Jan Petter Stiff, Crux Advisers

stiff@crux.no
+47 995 13 891

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to section 5-12 of the Norwegian Securities Trading Act.

Kilde

[Ekornet]

YES!! “For a subset… median OS not reached at >16 months”. Sånt blir det medisin av i high unmet need kategorier!! Blåser i om det tar 1,2, eller 3 år, gud bedre dette var digg.

Som de skriver så ser man mye på hvilke av pasientene som har mest nytte av denne behandlingen, hva kjennetegner de tilfellene som responderer best, feks den nylige doktograden ved uib, vil tro at dette blir viktig mtp oppsettet av en pivotal trial.

De skriver også om tett dialog med EMA og FDA, (fast track), jeg vil tro man kan lage en mindre og effektiv studie og med disse resultatene her burde ikke inklusjon bli noe problem!

Happy days!!

[Neonsun]

36% CR /CRi også på dette subsettet (lav N så forbehold der så klart), så med biomarkør på plass så kan dette bli veldig bra for målgruppen som responderer.

[Skeptikern]

@Ekornet

For a subset… median OS not reached at >16 months

Hva er forventete mOS for tilsvarende subset fra historiske kontroller da? Ser at de sier historiske kontroller er 4.1-5.6 mnd, men det er vel ikke for tilsvarende subset som mottar 2 eller flere sykluser med LDAC, men alle inkludert de som dør eller faller fra før de rekker å motta 2 sykluser? Eller fjernes “tidlige frafall” fra historiske kontroller også? (Beklager om det er dumt spørsmål er ikke fra dette fagfeltet)

[busk1]

Synes ikke det er et dumt spørsmål. Opplagt fare for overlevelsesbias i den måten å velge ut undergrupper på. Skulle gjerne sett fordelingen på overlevelsestid for alle på LDAC i en tilsvarende populasjon for å se om det er vanlig å ha en undergruppe med langtidslevende selv om medianoverlevelsen er lav.

EDIT: Nå er dette en gruppe med skrøpelige, eldre pasienter som tidligere har hatt effekt av en behandling og som har fått tilbakefall. Noen som vet hva slags behandling de da mest sannsynlig har fått fra før? Er det LDAC eller noe annet?

[InfoLeecher]

@TekBot

In a subset of eleven relapsed AML patients, who received two or more cycles of
the combination, an increased clinical benefit was demonstrated;

Noen som har tilgang på posteren?
Hva var det som skilte ut subsettet.

Fikk bare de i dette subsettet “2 or more cycles of the combination”?
Om det er tilfellet viser det jo at flere doseringer gir vesentlig bedre effekt og survival.
Men det høres ut som noe annet enn number of combocycles var skillet for subsettet.

[busk1]

Posteren ligger på hjemmesiden til Bergenbio.

Så vidt jeg kan se er utvalgskriteriet kun at de har fått minst 2 behandlinger. Og så lister de 3 karakteristikker for gruppen, der 2 av egenskapene er at de har fått 2 behandlinger og nok tid til å få to behandlinger. Jeg synes ikke det er så tillitvekkende dataanalyse, for å være ærlig. Jeg klarer ikke å tolke beinmargsanalyseplottene så vet ikke om de gir en bedre begrunnelse for hvorfor disse pasientene lever lenger.

Vi ser at behandlingstiden på Bem+LDAC er relativt kort sammenlignet med overlevelsestiden. Jeg lurer på hva pasientene har fått av behandling i etterkant av denne behandlingen. Har det påvirket overlevelsen?

[InfoLeecher]

takker. ettersom det sto i meldinga at poster var tilgjenglig for de som hadde registret seg på konferansesiden. Så antok jeg bare at selskapet ikke hadde den på siden sin.

Enig i betrakningen din om utvalget i dataanalysen. De bør ha en god argumentasjon for å trekke ut det utvalget i såfall.
Utfra de 2 benmargsplotta ser det ut for meg at de hadde både non-responders og responders for alle type celler
Jeg er kunnskapløs i medisinfelter da.

Utfra hele datasettet ser det ut til at Refractory ikke hadde respons å snakke om. Lavere antall enn relapsed. Så kanskje for tidlig å droppe refractory i neste runde.

[TekBot]

BerGenBio ASA: Increase of share capital, exercise of share options and disclosure of trade by primary insider

Bergen, Norway, 11 June 2021

The Board of Directors in BerGenBio ASA (the “Company”) (OSE: BGBIO) have, to
…

Vis børsmeldingen

fulfil the Company’s obligations under the share option agreements and in
accordance with the authorization granted by the general meeting on 19 March
2021, today resolved to increase the Company’s share capital by NOK 7,500 by
issuance of 75,000 new shares. The new shares are subscribed for by option owner
who wishes and are entitled to exercise options in accordance with the Company’s
option scheme. Each option gives a right to receive one share in the Company.
The subscription price is in accordance with the prevailing options price
pursuant to the Company´s option scheme NOK 10.62 per share.

The 75,000 options are exercised by primary insider Richard Godfrey (CEO) and
the options are granted 13 June 2013 and expiry on 13 June 2021. Primary insider
notification pursuant to the market abuse regulation article 19 is attached.

The primary insider has transferred his rights to receive shares resulting from
the exercise of options to a third party. The third party has sold the shares at
a price of NOK 25.67 per share.

Following the exercise, primary insider Richard Godfrey are holding 1,684,978
options in the Company of which 1,096,462 is vested, in addition to 21,005
shares in the Company through Gnist Holding AS.

The capital increase is expected to be registered within 7 days, and following
the issuance of the new shares, the issued share capital of BerGenBio ASA will
be NOK 8,796,275.50 consisting of 87,962,755 shares, each with a par value of
NOK 0.10.

-End-

Contacts

Richard Godfrey

CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie

CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to the
market abuse regulation article 19 and section 5-12 of the Norwegian Securities
Trading Act.

Kilde

[Inveliten]

@TekBot

Following the exercise, primary insider Richard Godfrey are holding 1,684,978
options in the Company of which 1,096,462 is vested, in addition to 21,005
shares in the Company through Gnist Holding AS.

Hvem er det som korrekturleser disse?

[Neutral]

Hva var galt i det utdraget?

[Inveliten]

To be bøyes “is” for tredjeperson entall, “are” for tredjeperson flertall?

[Neutral]

Shit… Vedkommende bør straffes, og ny melding bør sendes ut førstkommende mandag. Her er det ikke rom for en liten menneskelig feil.

@pdx bare fjern

[Hocjoc]

Jeg la merke til det samme. Jeg synes det er underlig dersom et børsnotert selskap ikke har rutiner som sikrer at det som publiseres av offentlig informasjon, er riktig skrevet. Det viktigste er selvsagt innholdet, men et poeng er også å fremstå som seriøs og «proff».

De oppnår ikke det når man kunne tro de hadde overlatt skrivingen til en ungdomsskoleelev på arbeidsuke.

[tverilytt]

USA skal investere 25 milliarder i coronapiller